Can rheumatoid arthritis cause demyelinating polyneuropathy?

Can Rheumatoid Arthritis Cause Demyelinating Polyneuropathy?

Yes, rheumatoid arthritis can cause demyelinating polyneuropathy, though this is rare and occurs through two distinct mechanisms: as a direct RA-related complication or as an iatrogenic effect of TNF-inhibitor therapy.

Direct RA-Associated Demyelinating Neuropathy

While uncommon, demyelinating polyneuropathy can occur as a primary manifestation of RA itself. A documented case demonstrated a patient developing Lewis-Sumner syndrome (a chronic inflammatory demyelinating polyradiculoneuropathy variant) concurrently with RA, with both conditions responding to rituximab therapy 1. Another case series from 1991 described a patient with RA who developed demyelinating neuropathy with elevated CSF protein, representing chronic inflammatory neuropathy occurring directly in the context of RA 2.

The more common neuropathic pattern in RA is axonal rather than demyelinating, typically presenting as:

• Vasculitic mononeuropathy multiplex (most characteristic)
• Distal symmetrical sensorimotor polyneuropathy (usually axonal)
• Compression neuropathies, especially carpal tunnel syndrome 3

TNF-Inhibitor-Induced Demyelination

The risk of demyelinating disease is significantly increased with anti-TNF therapy, making this the more clinically relevant concern. Anti-TNF drugs are known to trigger or exacerbate demyelinating syndromes and are consequently contraindicated in patients with multiple sclerosis and related disorders 4. This risk extends to newer TNF inhibitors, as demonstrated by a 2025 case report of ozoralizumab-induced multifocal demyelinating neuropathy in a 57-year-old male with RA, which resolved after discontinuing the drug and administering IVIG 5.

Clinical Implications and Management Algorithm

When demyelinating polyneuropathy occurs in RA patients:

1. Determine the etiology:

   • Review medication history for TNF-inhibitor exposure
   • Assess RA disease activity and severity (severe RA with RF >169.10 IU/mL increases neuropathy risk 6)
   • Obtain nerve conduction studies to confirm demyelination pattern

2. If TNF-inhibitor-associated:

   • Immediately discontinue the TNF-inhibitor
   • Consider IVIG therapy (effective in documented cases 5)
   • Switch to non-TNF biologics: rituximab or abatacept are preferred alternatives 1

3. If RA-related (no TNF-inhibitor exposure):

   • Initiate corticosteroids (effective in stabilizing or improving symptoms 2)
   • Consider rituximab as first-line biologic, which treats both RA and the demyelinating component 1
   • Plasma exchange for severe cases
   • Note: IVIG is largely ineffective for autoimmune nodopathy variants 7

Critical Pitfalls to Avoid

• Do not assume all RA neuropathy is compressive or axonal—obtain nerve conduction studies when clinical suspicion exists
• Never initiate or continue TNF-inhibitors in patients with demyelinating disease history 4
• Recognize that severe RA activity (high RF, elevated CRP) predicts neuropathy risk—patients with RF >169.10 IU/mL have 8-fold increased odds of peripheral neuropathy 6
• The association between RA and chronic inflammatory demyelinating polyradiculoneuropathy remains exceptional outside of TNF-inhibitor exposure 1

In summary: demyelinating polyneuropathy in RA is rare but real, occurring either as a direct RA complication or more commonly as a TNF-inhibitor adverse effect, with rituximab emerging as the optimal biologic choice when both conditions coexist.